MedTrace Logo

Influence of Oxycodone on Individuals Taking an SSRI

NCT05730062 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-02-15

No results posted yet for this study

Summary

This study will determine whether selective serotonin reuptake inhibitors (SSRI) exacerbate opioid induced respiratory depression in patients initiating treatment for underlying conditions such as depression or an anxiety disorder. Next to paroxetine which has been evaluated in a previous study in healthy volunteers sertraline, citalopram and escitalopram will be evaluated with regards to its influence on opioid induced respiratory depression.

Conditions

  • Opioid Induced Respiratory Depression
  • Depressive Disorder
  • Anxiety Disorders

Interventions

DRUG

Oxycodone Hydrochloride

Oxycodone 10 mg IR

DRUG

Placebo

placebo comparator

Sponsors & Collaborators

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Albert Dahan, MD PhD · LUMC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2025-01-15
Completion
2025-04-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05730062 on ClinicalTrials.gov